Mirvedol (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist at the NMDA receptor, blocking excessive calcium influx that can cause neuronal injury. This modulation protects brain cells while allowing normal synaptic transmission, which may slow cognitive decline in Alzheimer’s disease.

The dosage of Mirvedol is individualized by the prescribing clinician based on the patient’s condition, renal function, and response to therapy. The prescriber determines the appropriate starting dose and any subsequent titration.

The safety of memantine in pregnancy and lactation has not been definitively established. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Mirvedol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirvedol (memantine) belongs to the NMDA‑receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe disease and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Mirvedol tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and keep out of reach of children.

Mirvedol is taken orally, usually once daily after a meal. The tablet should be swallowed whole with water and not crushed or chewed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, can include seizures, cardiac arrhythmias, severe allergic reactions such as Stevens‑Johnson syndrome, and hallucinations or psychosis. Patients should be monitored for these symptoms and seek immediate medical attention if they occur.

Mirvedol is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑receptor antagonists.